Who Should Evaluate GLP-1 Use in Hashimoto's and What to Discuss Patients with Hashimoto's who are candidates for GLP-1 therapy must have separate clinical indication (obesity, type 2 diabetes, cardiovascular risk) and stable thyroid disease controlled on levothyroxine
#ORN2025 #FentanylResearch #OpioidUseDisorder #AddictionScience #PublicHealth #Research #AddictionMedicine #BehavioralHealth #NAVandAssociates #SAMHSA To view or add a comment, sign in If you ever wonder why I work at the Center for Dissemination & Implementation At Stanford (C-DIAS), this article details why
Now, in a similar way, who is not a good candidate for these medications
Borg MJ, Bound M, Grivell J et al (2019) Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes